AGERA LABORATORIES, INC. – Trademark Portfolio
Entity Type: 03
AGERA LABORATORIES, INC. holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 12 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include MAGC, AGERA, AGERA RX, PROLIFERSYN, and REPLENISH. REPAIR. RENEW. The owner is based in Horsham, PA.
111 Rock Road
Horsham, PA 19044
Showing of trademarks Trademarks
Trademark Classifications
AGERA LABORATORIES, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does AGERA LABORATORIES, INC. have?
AGERA LABORATORIES, INC. has 13 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 abandoned, 7 cancelled.
What trademark classes does AGERA LABORATORIES, INC. file in?
AGERA LABORATORIES, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are AGERA LABORATORIES, INC.'s most well-known trademarks?
AGERA LABORATORIES, INC.'s registered trademark portfolio includes well-known marks such as MAGC, AGERA, AGERA RX, PROLIFERSYN, and REPLENISH. REPAIR. RENEW. These are among 5 currently registered trademarks in the portfolio.
What is AGERA LABORATORIES, INC.'s trademark registration success rate?
AGERA LABORATORIES, INC. has a 38% trademark registration rate, with 5 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.